President Donald Trump has signed an executive order aimed at accelerating the review process for psychedelic drugs. This directive seeks to loosen existing restrictions and speed up access to these substances.
The order specifically targets the use of psychedelics, including LSD, psilocybin, and ibogaine, for the treatment of various mental health disorders. The administration is pushing for increased research into their therapeutic potential.
This move is expected to significantly accelerate the availability of these treatments. This is a developing story and will be updated as details emerge.
